Patents Assigned to Boehringer Ingelheim Vetmedica, Inc.
  • Patent number: 10201599
    Abstract: The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis, and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: February 12, 2019
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Jeremy Kroll, Mike Roof
  • Patent number: 10168330
    Abstract: The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: January 1, 2019
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Arun V. Iyer, Joseph Ralph Hermann, Michael B. Roof, Eric Martin Vaughn, Merrill Lynn Schaeffer
  • Patent number: 10131696
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: November 20, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Luis Alejandro Hernandez, Christine Margaret Muehlenthaler, Eric Martin Vaughn, Gregory Haiwick
  • Publication number: 20180271969
    Abstract: The present invention relates to an immunogenic composition comprising polysaccharide-protein conjugates wherein each conjugate contains a capsular polysaccharide prepared from Streptococcus suis serotypes 1, 2, 7 and/or 9 or any other serotype conjugated to a carrier protein. The immunogenic composition is useful for the protection of disease in an animal subject.
    Type: Application
    Filed: October 6, 2016
    Publication date: September 27, 2018
    Applicants: Boehringer Ingelheim Vetmedica, Inc., Université de Montréal, Université du Québec à Montréal
    Inventors: Marcelo GOTTSCHALK, Guillaume GOYETTE-DESJARDINS, Jennifer Anne Kempker, Axel NEUBAUER, René ROY, Mariela SEGURA, Tze Chieh SHIAO
  • Patent number: 10010603
    Abstract: The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: July 3, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Vicky Fachinger, Knut Elbers, Axel Lischewski, Marion Kixmoeller, Francois-Xavier Orveillon, Isabelle Freiin Von Richthofen, Michael D. Piontkowski
  • Patent number: 10010604
    Abstract: The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: July 3, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Vicky Fachinger, Knut Elbers, Marion Kixmoeller, Francois-Xavier Orveillon, Isabelle Freiin Von Richthofen, Axel Lischewski
  • Patent number: 9987349
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: June 5, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael B Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 9962435
    Abstract: The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection against North American Dominant West Nile Virus strains or isolates.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: May 8, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Kristina J. Hennessy, Phillip Wayne Hayes
  • Patent number: 9950061
    Abstract: The present invention relates to a vaccine for protecting a pig against diseases associated with porcine epidemic diarrhea virus. The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and methods of producing the porcine epidemic diarrhea virus vaccine are also provided.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: April 24, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Luis Alejandro Hernandez, Arun V. Iyer, Dianna M. Murphy Jordan, Abby Rae Patterson, Michael B. Roof, Eric Martin Vaughn, Joseph Gilbert Victoria
  • Patent number: 9943587
    Abstract: The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment of sub-clinical PCV2 infection in animals, preferably in pigs.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: April 17, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Vicky Fachinger, Knut Elbers, Marion Kixmoeller, Francois Xavier Orveillon, Isabelle Freiin von Richthofen, Axel Lischewski
  • Patent number: 9925256
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: March 27, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel
  • Patent number: 9925255
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: March 27, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael B. Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel
  • Patent number: 9919041
    Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: March 20, 2018
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 9833507
    Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5A (PPV5A) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 5, 2017
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Arun V. Iyer, Dianna M. Murphy Jordan, Abby Rae Patterson, Michael B. Roof, Eric Martin Vaughn, Joseph Gilbert Victoria, Callie Ann Visek
  • Patent number: 9827306
    Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5B (PPV5B) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: November 28, 2017
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Arun V. Iyer, Dianna M. Murphy Jordan, Abby Rae Patterson, Michael B. Roof, Eric Martin Vaughn, Joseph Gilbert Victoria, Callie Ann Visek
  • Patent number: 9669087
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: June 6, 2017
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael B Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
  • Patent number: 9669086
    Abstract: Multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of M. hyo infection, preferably M. hyo bacterin, or an immunogenic composition comprising M. hyo bacterin, and at least one immunogenic active component of another disease-causing organism in swine, preferably PCV2 wherein the preferred PCV2 antigen for such a multivalent vaccine is PCV2 ORF 2 protein.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: June 6, 2017
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael Roof, Marc Eichmeyer
  • Patent number: 9636389
    Abstract: The present invention relates to the use of porcine circovirus type 2 (PCV2) antigen and Lawsonia intracellularis (L. intracellularis) antigen for the prevention, reduction in severity of, lessening of the clinical symptoms associated therewith, reduced incidence in a herd, and treatment of swine against Porcine Circovirus Associated Diseases (PCVAD) and L. intracellularis associated diseases. In particular, the present invention provides a method for the treatment or prophylaxis of an animal against PCV2 infection and ileitis caused by L. intracellularis, or a method for reduction of clinical symptoms caused by or associated with a PCV2 and L. intracellularis infection, comprising the step of administering an effective amount of PCV2 antigen and L. intracellularis antigen to an animal in need of such treatment.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: May 2, 2017
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Vicky Fachinger, Knut Elbers
  • Patent number: 9624527
    Abstract: The invention provides methods and mass-labeled peptides for use in said methods for quantifying the presence of a one or more viral proteins in a sample of a preparation containing agents which bind to said viral protein, using mass-spectroscopic analyzes of the sample and standards containing known amounts of labeled and unlabeled signature peptides, in particular wherein said viral proteins are antigens in a vaccine for porcine circovirus.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: April 18, 2017
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Marc Allan Eichmeyer, Michael B. Roof, Merrill Lynn Schaeffer, Eric Martin Vaughn, Kun Yang, Jeremy Richard Rush, Daniel John Murfin
  • Patent number: 9610345
    Abstract: The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: April 4, 2017
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael B Roof, Phillip Wayne Hayes, Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer